CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

CRISPR Therapeutics AGNASDAQ: CRSP

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $71.89M rose 22.0% year over year, ahead of the +1.6% change in trailing-twelve-month research & development. Sequentially, it rose 10.7% from the prior quarter. Over 3 fiscal years it compounded at -16.9% a year.

Context

  • Research & development amounted to 7559.2% of revenue in FY2025, up 6643.0 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.0% holds above the trailing-twelve-month pace of +1.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$71.89M+10.7% QoQ
Last fiscal yearDec 2025
$265.33M-17.3% YoY
LTMSep 2026
$283.28M+1.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.0%——
1 year-17.3%——
3-year CAGR-16.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
265.33M USD
Year-over-year change
-17.3%
4-year CAGR
-6.1%

Research & Development vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 research & development of $283.28M is the 3rd highest of the 7 companies compared; the peer median is $225.71M.
  • Its year-over-year change of +1.6% is the 3rd highest of 7, against a peer median of -16.2%.
  • Research & development amounts to 1125.4% of revenue for CRSP, versus a peer median of 215.7%.
CRSP Competitors Peer median
Research & Development for CRSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BEAMBeam Therapeutics Inc.LTM Jun 2026$408.66M +3.1%+9.5%261.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M -21.5%-2.5%546.5%
CRSPCRISPR Therapeutics AGLTM Sep 2026$283.28M +1.6%-16.9%1125.4%
RGNXREGENXBIO Inc.LTM Mar 2026$228.65M +12.8%-2.0%260.4%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$222.77M -37.9%-38.6%157.6%
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M -62.3%-19.9%171.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$53.36M -10.8%+5.5%118.4%
Peer median (excluding CRSP) $225.71M-16.2%-2.3%215.7%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue913.08M436K370M35M3.51M
Cost of Revenue101.18M110.25M130.25M110.25M232.96M
Gross Profit811.9M(109.81M)239.75M(75.25M)(229.45M)
Gross Margin88.9%-25186.7%64.8%-215.0%-6537.0%
Research & Development340.57M461.65M387.33M320.65M265.33M
Selling, General & Admin99.69M102.46M76.16M72.98M73.54M
Operating Expenses438.38M563.35M462.29M391.32M338.87M
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
EBITDA397.48M(626.33M)(130.89M)(343.41M)(558.49M)
EBITDA Margin43.5%-143653.2%-35.4%-981.2%-15911.3%
Operating Income373.53M(673.16M)(222.54M)(466.57M)(568.32M)
Operating Margin40.9%-154394.7%-60.1%-1333.0%-16191.4%
Interest Income00000
Interest Expense00000
Other Income / Expenses6M22.66M71.82M103.9M(9.65M)
Income Before Tax379.53M(650.5M)(150.72M)(362.67M)(577.97M)
Pre-Tax Margin41.6%-149197.2%-40.7%-1036.2%-16466.2%
Income Tax Expense1.87M(325K)2.89M3.59M3.63M
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Net Margin41.4%-149122.7%-41.5%-1046.4%-16569.8%
EPS (Basic)4.97(8.36)(1.94)(4.34)(6.47)
EPS (Diluted)4.70(8.36)(1.94)(4.34)(6.47)
Weighted Avg Shares75.95M77.75M79.22M84.36M89.93M
Weighted Avg Shares (Diluted)80.39M77.75M79.22M84.36M89.93M

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.